Phase III trial for beloranib successful to treat obesity complicated byType 2 diabetes- Zafgen Inc.

Zafgen Inc. announced new data from the ZAF 203 clinical trial evaluating beloranib, a MetAP2 inhibitor, for the treatment of severe obesity complicated by type 2 diabetes. Data presented during the American Diabetes Association's 76th Scientific Sessions showed that beloranib was associated with improvement in body composition, including a significant decrease in body weight, fat mass, reduction in waist and hip circumference, and improvements in liver fat, as well as glycemic control parameters including HbA1c, fasting plasma glucose (FPG), post-prandial glucose, beta-cell function, and insulin sensitivity, when compared to placebo.

As previously reported, the ZAF 203 clinical trial achieved its primary efficacy endpoint, as beloranib demonstrated a statistically significant reduction in body weight compared to placebo. Patients enrolled in both the 1.8 mg and 1.2 mg treatment arms also met a key secondary endpoint, with patients in each dose arm achieving, on average, an absolute reduction in HbA1c following six months of treatment of 2.0 percent compared to a reduction of 0.6 percent for placebo.